FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience
This article was originally published in The Pink Sheet Daily
A long-time FDA veteran who remains largely unknown to the generics industry, Kathleen Uhl replaces CDER Director Janet Woodcock as acting director of the Office of Generic Drugs effective March 19 following Gregory Geba’s March 15 departure from the generic office’s top post.
You may also be interested in...
Implementer of many drug review changes will leave in January after nearly 32 years of public service.